DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S. et al.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Lancet Oncol 2019;
20: 625-35
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.